Blanket Purchase Agreement V797D50358-36C24820A0022
Award Date 3/16/20
Last Date to Order 9/30/21
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed Similar IDVs
- CSL Behring L.L.C., a global biotherapeutics company headquartered in King of Prussia, Pennsylvania, was awarded a multiple-award Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs by Veterans Integrated Service Network 12 on September 30, 2021, with a ceiling value of $201.48 million and performance through September 29, 2026. Under this indefinite delivery vehicle, CSL Behring serves as a prime contractor supplying specialty pharmaceutical products to the Department...
- CSL Behring L.L.C., a global biotherapeutics company headquartered in King of Prussia, Pennsylvania, was awarded a single-award Blanket Purchase Agreement by the National Acquisition Center on September 30, 2021, for the procurement of HAEGARDA, a C1 inhibitor medication used to treat hereditary angioedema. The BPA carries a ceiling value of $17.5 million and extends through September 29, 2026, with performance conducted at CSL Behring's manufacturing and distribution facility in King of...
- This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 7 to procure HAEGARDA 2000 and 3000 units/vials of medication to treat hereditary angioedema. The contract was awarded to CSL Behring L.L.C. under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) with a potential value of $113,280. The period of performance is from April 1, 2023 through June 30, 2023. The agreement facilitates orders for...
- Grifols USA LLC holds a $1.38 billion Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs awarded by the Department of Veterans Affairs (VA), Veterans Integrated Service Network 12 on May 1, 2022, with an ultimate completion date of April 30, 2027. This multiple-award indefinite delivery vehicle procures pharmaceutical products without set-aside designations, reflecting Grifols' status as a large business. The primary product supplied under this contract is PROLASTIN-C...
- B. Braun Medical Inc., a manufacturer of medical devices and pharmaceutical products headquartered in Bethlehem, Pennsylvania, was awarded a Federal Supply Schedule contract under General Services Administration (GSA) schedule 61-IB (Pharmaceuticals and Drugs) on May 1, 2018, with a ceiling value of $700,000.00 and ultimate completion date of May 1, 2026. This multiple-award contract, funded by the Veterans Integrated Service Network 12 under the Department of Veterans Affairs, carries no...
- The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
- This Blanket Purchase Agreement, awarded to Gilead Sciences Inc. on November 1, 2022, establishes a single-award indefinite delivery vehicle valued at $29.16 million through October 31, 2026. The contract is administered by the National Acquisition Center, a civilian federal agency, and operates under the General Services Administration's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The BPA covers the procurement and delivery of four specialized pharmaceutical products:...
- The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
- Adma Biologics, Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) by the National Acquisition Center with a ceiling value of $49 million for the supply of ASCENIV and BIVIGAM, plasma-derived therapeutic pharmaceuticals. The BPA was awarded on August 1, 2024, and extends through July 31, 2026, with no small business set-aside applied. As the prime contractor, Adma Biologics will supply these specialized hematology-related products to federal agencies, primarily supporting...
- Octapharma USA Inc. has been awarded a Federal Supply Schedule contract under the Pharmaceuticals and Drugs schedule (FSS-61-IB) by Veterans Integrated Service Network 12, a civilian agency within the Department of Veterans Affairs. This multiple-award contract, valued at $572,330.00 with an ultimate completion date of July 31, 2026, represents a temporary contract extension with no set-aside used in the procurement. The contract authorizes the supply of blood plasma products and related medical...
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
BPA Call 36C24820A0022-36C24820N0622 | CSL Behring L.L.C. | $25.2k | 6/4/20 | 6/30/20 | 6/4/20 | |
BPA Call 36C24820A0022-36C24820N0836 | CSL Behring L.L.C. | $136.4k | 8/20/20 | 8/24/20 | 8/20/20 | |
BPA Call 36C24820A0022-36C24820N0592 | CSL Behring L.L.C. | $136.4k | 5/20/20 | 5/25/20 | 5/20/20 | |
BPA Call 36C24820A0022-36C24820N0571 | CSL Behring L.L.C. | $20.0m | 5/8/20 | 5/31/20 | 5/8/20 | |
BPA Call 36C24820A0022-36C24820N0737 | CSL Behring L.L.C. | $136.4k | 7/22/20 | 7/31/20 | 7/22/20 |